Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Mar 10, 2026
Why Is Centene Corporation (CNC) Stock Down -10% Today?

Why Is Centene Corporation (CNC) Stock Down -10% Today?

Key Takeaways

  • CNC shares fell approximately 10% during Tuesday's session, extending a prolonged selloff in the managed care sector
  • The primary catalyst is intensifying investor concern over federal Medicaid and ACA funding cuts tied to the "One Big Beautiful Bill Act" (OBBBA), which threatens to shrink the government-sponsored insurance pools that Centene depends on for the majority of its revenue
  • Secondary pressure stems from a sector-wide reassessment of Medicare Advantage payment rates following the Trump administration's January 2026 proposal to keep 2027 rates nearly flat at just 0.09% net growth, far below the 4%–6% analysts had expected
  • Peer managed-care names including UNH, HUM, ELV, and MOH have all registered significant declines in the same period, underscoring this is a sector-level event rather than a company-specific shock
  • Elevated medical cost ratios, declining Medicaid enrollment, and continued negative net income compound the bearish backdrop for Centene
  • Traders are watching the finalization of the 2027 Medicare Advantage rate (expected in April 2026) and any updates to OBBBA implementation as near-term catalysts

Opening Summary

Centene Corporation (CNC) is one of the largest managed care organizations in the United States, providing government-sponsored health insurance through Medicaid, Medicare Advantage, and Affordable Care Act (ACA) marketplace plans to more than 28 million members. Shares plunged approximately 10% in Tuesday's session, falling from a prior close of roughly $43.16 to trade near $38.85, as the managed care sector faced a renewed wave of selling pressure. The move reflects deepening fears around federal healthcare funding policy, a structural reset in Medicare Advantage payment rates, and the potential erosion of Centene's core government-sponsored membership base.

Policy Shock: Medicare Advantage Rates and OBBBA

The proximate driver behind managed care's extended decline — and CNC's sharpest single-session drop — is federal policy headwinds hitting the sector from multiple directions. In late January 2026, the Centers for Medicare & Medicaid Services (CMS) proposed a net average payment increase for 2027 Medicare Advantage rates of just 0.09%, compared to analyst expectations of 4%–6% growth. In real terms, adjusted for medical cost inflation, the proposal amounts to a meaningful funding cut for insurers. CMS also proposed tightening risk-adjustment rules — including excluding diagnoses made only via audio-only telehealth visits — further compressing the margins that insurers use to manage sicker, costlier patient populations.

 

Layered on top of the rate shock is the legislative overhang from the "One Big Beautiful Bill Act," which tightened ACA marketplace enrollment requirements, reduced Medicaid financing, and is expected to leave millions without coverage. For Centene, which derives the bulk of its revenue from Medicaid and ACA plans, any contraction in eligible enrollment directly shrinks the addressable market. Investors are recalibrating how much of this policy-driven margin compression is already priced in — and Tuesday's price action suggests many concluded it was not enough.

Sector Contagion and Peer Sympathy Selling

Centene's decline did not occur in isolation. The entire managed care space has come under severe pressure since the Medicare rate proposal, with UNH losing more than 19%, HUM plunging over 20%, and ELV falling roughly 13% on the initial announcement day in late January. Tuesday's continued selling reflects lingering uncertainty about whether the final April rate notice will be any more favorable, as well as broader investor fatigue with the sector's persistent earnings challenges. CNC — with a more diversified revenue base than pure-play Medicare Advantage insurers — saw a relatively moderate initial drop of around 10%, but the overhang has continued to weigh on the stock in subsequent sessions.

Fundamental Pressures Amplify the Selloff

Beyond the policy backdrop, Centene's own fundamentals leave little margin for error. The company posted a net loss of $1.19 per share in its most recent quarter, which beat estimates of a $1.22 loss but still represents a continued period of negative profitability. The company carries a debt-to-equity ratio of approximately 2.84, and its trailing twelve-month net income sits at a loss of roughly $5.29 billion. While management has set 2026 full-year EPS guidance of $3.00 and analysts project an eventual recovery to $6.86 EPS for the full year, the path to those numbers has narrowed significantly given the rate and regulatory environment. The consensus analyst rating remains "Hold" with a price target that has drifted close to current trading levels, leaving minimal institutional support to absorb selling pressure.

Market Context and Trading Activity

Volume in CNC has been running significantly above its average during managed care's most volatile sessions, with the January selloff day printing over 16 million shares — nearly double the typical daily turnover. The stock remains well below its 52-week high of $66.81, having now surrendered most of the recovery it mounted from the July 2025 low of $25.08. The managed care ETF IHF and the broader healthcare index both underperformed the general market during Tuesday's session, confirming that the move is sector-driven rather than idiosyncratic to Centene. From a technical standpoint, the stock has been oscillating between key support near $37.50 and resistance at $47.50, and Tuesday's break lower puts the next meaningful support level back in focus.

Trending AI Robots

For traders navigating volatile sessions like today's in managed care, Tickeron's Trending AI Robots page offers a curated view of the platform's best-performing automated trading bots under current market conditions. Tickeron operates hundreds of AI-powered trading bots covering thousands of tickers across sectors and asset classes, but only the strongest performers — ranked by recent metrics such as win rate, annualized return, and drawdown — appear in the Trending section. Bots vary widely in strategy (momentum, mean reversion, breakout), timeframe (intraday to swing), and the specific symbols they trade. Whether a trader is looking to capitalize on sector dislocations, hedge existing positions, or automate a rules-based approach, the Trending AI Robots section provides a practical starting point for discovering which strategies are working right now.

What Comes Next for CNC

The most consequential near-term event for CNC is the finalization of the 2027 Medicare Advantage payment rate, expected from CMS in April 2026. A final rate meaningfully above the proposed 0.09% could serve as a significant catalyst for a sector-wide recovery, while a confirmation of near-flat rates would likely extend the current bear phase. Centene's next earnings release is scheduled for April 28, 2026, at which point management will need to update guidance in light of the evolving policy landscape. Analysts will be closely watching the medical loss ratio trajectory, any changes in Medicaid enrollment following OBBBA implementation, and whether the company's expanding commercial marketplace business — which grew membership 29.5% in 2025 — can offset government program headwinds. Regulatory developments around risk-adjustment methodology changes and any further CMS rule proposals will also shape the stock's path heading into the back half of 2026.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitation

Related Ticker: CNC

Aroon Indicator for CNC shows an upward move is likely

CNC's Aroon Indicator triggered a bullish signal on July 10, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 216 similar instances where the Aroon Indicator showed a similar pattern. In of the 216 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on June 30, 2026. You may want to consider a long position or call options on CNC as a result. In of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CNC advanced for three days, in of 306 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for CNC moved out of overbought territory on June 11, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

The Moving Average Convergence Divergence Histogram (MACD) for CNC turned negative on July 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CNC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CNC broke above its upper Bollinger Band on July 01, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. CNC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.584) is normal, around the industry mean (5.188). P/E Ratio (9.063) is within average values for comparable stocks, (51.544). Projected Growth (PEG Ratio) (1.324) is also within normal values, averaging (1.453). CNC's Dividend Yield (0.000) is considerably lower than the industry average of (0.018). P/S Ratio (0.171) is also within normal values, averaging (0.707).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CNC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.

Notable companies

The most notable companies in this group are Unitedhealth Group (NYSE:UNH), CVS HEALTH Corp (NYSE:CVS), Elevance Health (NYSE:ELV), Cigna Group (The) (NYSE:CI), Humana (NYSE:HUM), Centene Corp (NYSE:CNC).

Industry description

Managed healthcare industry focuses on providing health/medical and disability insurance plans, generally intended to reduce the cost of for-profit health care. The insurance products might be provided through employer-paid (fully or partly) insurance and benefit programs, or through Medicare/Medicaid. Some of the largest providers of managed health care include Aetna, Humana Inc., and Cigna, and UnitedHealthcare.

Market Cap

The average market capitalization across the Managed Health Care Industry is 73.52B. The market cap for tickers in the group ranges from 1.01M to 386.13B. UNH holds the highest valuation in this group at 386.13B. The lowest valued company is IHGP at 1.01M.

High and low price notable news

The average weekly price growth across all stocks in the Managed Health Care Industry was 1%. For the same Industry, the average monthly price growth was 6%, and the average quarterly price growth was 36%. CI experienced the highest price growth at 6%, while ALHC experienced the biggest fall at -12%.

Volume

The average weekly volume growth across all stocks in the Managed Health Care Industry was 3%. For the same stocks of the Industry, the average monthly volume growth was -36% and the average quarterly volume growth was -40%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 37
P/E Growth Rating: 43
Price Growth Rating: 20
SMR Rating: 81
Profit Risk Rating: 88
Seasonality Score: 6 (-100 ... +100)
View a ticker or compare two or three
CNC
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a multi-line healthcare enterprise

Industry ManagedHealthCare

Profile
Details
Industry
Managed Health Care
Address
7700 Forsyth Boulevard
Phone
+1 314 725-4477
Employees
67700
Web
https://www.centene.com
Interact to see
Advertisement
Recent analyst upgrades from Piper Sandler and Morgan Stanley underscore improving valuation and renewed confidence in Motorola Solutions’ growth outlook. Third-quarter 2025 results exceeded expectations, with revenue increasing 7.8% year over year, driven by land mobile radio (LMR) and video security demand.
Hexcel Corporation (HXL), a leading supplier of advanced composite materials used across aerospace, defense, and industrial markets, has maintained steady momentum amid a shifting industry backdrop. Recent share performance reflects investor optimism around a gradual recovery in commercial aviation, balanced against concerns about production timing and cost pressures.
TSM’s upcoming earnings carry outsized importance for the semiconductor industry. As the world’s leading contract chip manufacturer, TSMC underpins AI innovation for customers such as Nvidia and Apple. Its results often serve as a bellwether for global chip demand, capacity constraints, and pricing trends.
Goldman Sachs (GS) is expected to report Q4 2025 EPS of $11.65 on revenue of $13.85 billion, reflecting steady results as investment banking activity continues to recover.
Citigroup (C) is expected to report Q4 2025 EPS of $1.58, representing a 17.9% year-over-year increase, with revenue projected at $20.95 billion, up 7%. Bank of America (BAC) consensus estimates call for Q4 EPS of $0.96, up from $0.82, on revenue of $27.74 billion, reflecting 9.45% growth. JPMorgan Chase (JPM) is forecast to deliver Q4 EPS of $4.86, a modest 0.95% increase, with revenue expected to rise 8.13% to $46.25 billion.
Wells Fargo (WFC) is expected to report Q4 2025 earnings on January 14, 2026, with consensus calling for EPS of $1.66, up 16.9% year over year, and revenue of approximately $21.66 billion, a 6.3% increase. Investor focus will center on net interest income stabilization, growth in fee-based businesses such as investment banking and mortgages, and credit provisioning in a lower-rate environment.
Wall Street expects Infosys Q3 FY2026 EPS of $0.20, based on estimates from eight analysts, with revenue forecast at ₹452.37 billion (approximately $5.45 billion), compiled from 33 analysts.
BitMine Immersion Technologies (BMNR) is set to report Q1 FY2026 earnings on January 16, 2026, with consensus estimates calling for EPS of $0.15 and revenue of approximately $79.3 million.
Bank of America (BAC) and Wells Fargo (WFC) will both report Q4 2025 earnings on January 14, 2026, creating a rare same-day, apples-to-apples comparison.
Citigroup (C) is set to report Q4 2025 earnings on January 14, 2026, making it the immediate catalyst in this comparison. HSBC Holdings (HSBC) will release its Full-Year 2025 results on February 25, 2026, positioning it as a medium-term earnings event.
Wells Fargo’s quarterly results carry broader significance because the bank serves as a key indicator of U.S. consumer and commercial banking conditions. Its earnings often influence sentiment toward the entire large-cap banking sector. After a stretch of improved market conditions and stronger capital markets activity, investors are looking for confirmation that profit momentum is sustainable rather than driven by a single favorable quarter.
Infosys (INFY) will report Q3 FY2026 results on January 14, 2026, making it the immediate catalyst in this comparison. Accenture (ACN) last reported Q1 FY2026 earnings on December 18, 2025, with its next update scheduled later in the fiscal quarter.
BMNR reported fiscal Q4 and full-year FY2025 results (ending August 31, 2025), with profitability heavily influenced by digital-asset accounting and treasury positioning. Full-year diluted EPS: $13.39; Net income attributable to common stockholders: $328.161 million.
M&T Bank (MTB) is expected to deliver Q4 2025 EPS of $4.44–$4.46, representing roughly 13% year-over-year growth, driven by improving net interest income as funding costs decline. PNC Financial Services Group (PNC) is projected to post Q4 EPS of $4.19–$4.23, supported by about 1.5% sequential NII growth from rate relief and steady loan demand. U.S. Bancorp (USB) is forecast to earn $1.19 per share, an 11.2% annual increase, with revenues estimated at $7.33 billion, up 5%.
Dash (DASH.X) has ignited the crypto market with a powerful mid-January 2026 breakout, rallying more than 125% in a single week and decisively outperforming fellow privacy coins such as Monero and Zcash. The surge was fueled by a sharp short squeeze that wiped out nearly $4.9 million in bearish positions, alongside a major catalyst: Dash’s integration with Alchemy Pay, enabling direct fiat purchases across 173 countries.
As 2026 gets underway, ether.fi’s governance token (ETHFI.X) is emerging as a focal point for traders seeking exposure to Ethereum’s rapidly expanding liquid restaking ecosystem. With total value locked climbing to $7.8 billion, ether.fi now ranks as the second-largest staking protocol after Lido, underscoring its growing influence in the Ethereum economy.
The Schwab U.S. Small-Cap ETF (SCHA) is holding firm near the $28 level as 2026 begins, even as broader markets remain volatile. While short-term price action has been uneven, underlying signals suggest the ETF may be setting up for a meaningful breakout as interest-rate cuts revive small-cap equities. Technical models highlight an unusually favorable risk-reward profile—up to 22:1—with long-term momentum strengthening despite near-term consolidation.
The Vanguard Small-Cap Value ETF (VB) is quietly standing out in what has been a turbulent start to 2026. While many small-cap segments have struggled, VB has shown notable resilience, including a 3.2% jump on January 14, driven by renewed buying interest in undervalued industrial and financial stocks. This divergence from broader small-cap weakness suggests early signs of mean reversion, particularly as incoming economic data points toward eventual interest-rate relief.
The Vanguard Russell 2000 ETF (VTWO) has entered 2026 with renewed technical strength, breaking through several key indicators that suggest a potential trend reversal. On January 2, 2026, VTWO’s Momentum Indicator moved decisively above zero, a signal often associated with the early stages of bullish cycles. This followed an earlier technical milestone in December 2025, when the 10-day moving average crossed above the 50-day, drawing attention from momentum and swing traders alike.
CAOS, the trading ticker for IRIS Energy Limited, is emerging as a standout performer in early 2026 as two powerful trends converge: Bitcoin’s renewed surge and explosive demand for AI-ready data infrastructure. As Bitcoin pushes higher and investors hunt for leveraged exposure to both crypto and artificial intelligence, CAOS has attracted increasing attention from retail and quantitative traders alike.